Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial - Verma, S; Mazer, C D; Fitchett, D (Diabetologia, 2018)